SFX by Ex Libris Inc.

Title:	RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis
Source:	Nature [0028-0836] Gonzalez Suarez, E yr:2010

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Schramek, D. "Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer." Nature 468.7320 (2010): 98-102.
description	2.	Bekker, Pirow J J. "A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women." Journal of bone and mineral research 20.12 (2004): 1059-66.
description	3.	Toyama, Y. "Receptor activator of NF-kappaB (RANK) ligand induces ectodomain shedding of RANK in murine RAW264.7 macrophages." The journal of immunology 184.5 (2010): 2442-2448.
description	4.	Jones, D Holstead H. "Regulation of cancer cell migration and bone metastasis by RANKL." Nature 440.7084 (2006): 692-6.
description	5.	Clohisy, D R R. "Bone cancer pain and the role of RANKL/OPG." Journal of musculoskeletal & neuronal interactions 4.3 (2004): 293-300.
description	6.	Liu, H. "p53 Control of Bone Remodeling." Journal of cellular biochemistry 111.3 (2010): 529-534.
description	7.	Colombo, M. "Sorafenib in advanced hepatocellular carcinoma: a further step toward personalized therapy of liver cancer." Gastroenterology 136.5 (2009): 1832-5.
description	8.	Dougall, W C C. "RANK is essential for osteoclast and lymph node development." Genes & development 13.18 (1999): 2412-24.
description	9.	Toussaint, E. "Causes of fever in cancer patients (prospective study over 477 episodes)." Supportive care in cancer 14.7 (2006): 763-9.
description	10.	Lewiecki EM, E Michael M. "Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD." Journal of bone and mineral research 22.12 (2007): 1832-41.
description	11.	Kozlow, W. "Breast Cancer Metastasis to Bone: Mechanisms of Osteolysis and Implications for Therapy." Journal of Mammary Gland Biology and Neoplasia 10.2 (2005): 169-180.
description	12.	Penninger, Josef M M. "RANKL-RANK signaling in osteoclastogenesis and bone disease." Trends in molecular medicine 12.1 (2005): 17-25.
description	13.	Rifkin, William D D. "Denosumab in postmenopausal women with low bone mineral density." The New England journal of medicine 354.8 (2006): 2390-1.
description	14.	Vahidi, A. "Identification and mutagenesis of the TACE and γ-secretase cleavage sites in the colony-stimulating factor 1 receptor." Biochemical and biophysical research communications 450.1 (2014): 782-787.
description	15.	Body, Jean-Jacques J. "A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer." Clinical cancer research 12.4 (2006): 1221-8.
description	16.	Bischoff-Ferrari, Heike A A. "Effect of Vitamin D on falls: a meta-analysis." JAMA 291.16: 1999-2006.
description	17.	Blair, C R R. "RANK ligand." The international journal of biochemistry & cell biology 39.6 (2007): 1077-81.
description	18.	Feldstein, J. "Tumour invasion and metastasis initiated by microRNA-10b in breast cancer." Nature 449.7163 (2007): 682-8.
description	19.	Zeisberg, M. "Fibroblasts in cancer." Nature reviews. Cancer 6.5 (2006): 392-401.
description	20.	Khaled, A. "Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology." Nano letters 5.9 (2005): 1797-808.